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A B S T R A C T
Estrone is the most abundant estrogen after the menopause. We developed a liquid chromatography-
tandem mass spectrometric method (LC–MS/MS) for determination of estrone in adipose tissue.
Subcutaneous adipose tissue from the breast was collected during elective surgery in postmenopausal
women undergoing mastectomy for treatment of breast cancer (n = 13) or reduction mammoplasty
(controls, n = 11). Homogenized adipose tissue was extracted with organic solvents and the estrone
fraction was purified by LH-20 column chromatography from the excess of lipids. The concentration of
estrone was analyzed by LC–MS/MS. The method was accurate with an intra-assay variation of 8% and an
interassay variation of 10%. The median concentration of estrone in subcutaneous adipose tissue from the
breast did not differ between breast cancer and control women, 920 pmol/kg and 890 pmol/kg,
respectively. In breast cancer patients but not in the controls, breast adipose tissue estrone levels
correlated positively with the serum estrone concentration. In conclusion, the new method provides a
reliable means to measure estrone concentrations in adipose tissue in postmenopausal women.
ã 2015 Elsevier Ltd. All rights reserved.
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In postmenopausal women, adipose tissue is the principal
source of estrogen [1]. The most abundant estrogen after the
menopause is estrone which is formed in peripheral tissues
primarily from androstenedione by aromatase, a cytochrome
p450 enzyme [2]. Activity of aromatase in adipose tissue is
positively related to weight and age in women [3,4]. Moreover,
there are relatively high concentrations of estrone sulfate in the
circulation which may be taken up and hydrolyzed to free estrone
in tissues by steroid sulfatase (STS) [5]. Estrogens are thought toAbbreviations: BMI, body mass index; GC–MS, gas chromatography-mass
spectrometry; IS, internal standard; LC–MS/MS, liquid chromatography–tandem
mass spectrometry; RIA, radioimmunoassay; STS, steroid sulfatase.
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0960-0760/ã 2015 Elsevier Ltd. All rights reserved.play an important role in the maintenance and growth of estrogen
receptor positive breast cancers [6,7].
The concentration of estrone in adipose tissue as reported in
postmenopausal women is several times higher than its circulating
levels [8,9]. Breast adipose tissue estrone levels have been shown
to correlate with body mass index (BMI) in postmenopausal
women [10]. Estrone is a precursor of 17b-estradiol in the
biosynthesis of estrogens in adipose tissue and, accordingly,
concentration of estrone is higher than that of 17b-estradiol in
breast adipose tissue as studied in breast cancer patients [8–12].
Estrone is more lipophilic compared to 17b-estradiol. The
previous reports on estrone concentrations in adipose tissue from
the breast have used radioimmunoassay (RIA) as the analytical
method [8–15]. When quantified in adipose tissue, the estrone
fraction needs to be separated from great amounts of free
cholesterol, triglycerides and other lipids that might otherwise
interfere with the analytical method for example by causing signal
suppression. In the present study, we describe a new quantitative
method to determine estrone in adipose tissue by liquid
chromatography-tandem mass spectrometry (LC–MS/MS), and
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Fig. 1. Outline of the method. Flowchart for quantitative determination of estrone
in adipose tissue by LC–MS/MS.
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subcutaneous adipose tissue from the breast in postmenopausal
women with or without breast cancer.
2. Materials and methods
2.1. Subjects
Subcutaneous adipose tissue from the breast was obtained from
postmenopausal women during mastectomy for treatment of
breast cancer (n = 13) or reduction mammoplasty (n = 11) as
described in [16]. Two distinct adipose tissue biopsies were taken
from every subject. Blood samples were collected before the
operation, and the tissue and blood samples were stored as
described in [16]. The study was approved by the Ethics committee
of Helsinki University Central Hospital and the subjects gave their
written informed consent.
2.2. Estrogens and solvents
Estrone (vetranal) was purchased from Sigma–Aldrich, St. Louis,
MO. [2,4,6,7-3H(N)]Estrone (specific activity 94 Ci/mmol) was
purchased from NEN, Boston, MA. Prior to use, [3H]estrone was
purified by Sephadex LH-20 column chromatography (GE Health-
care Bio-Sciences AB, Uppsala, Sweden) using 9% methanol in
toluene as eluent [17]. 13C3-estrone was purchased from Iso-
Sciences, King of Prussia, PA.
Methanol, hexane, diethyl ether and ethyl acetate were HPLC
grade (Rathburn Chemicals Ltd., Walkerburn, Scotland). Chloro-
form and toluene were purchased from Merck (Kenilworth, NJ).
2.3. Sample preparation
Control serum pools containing two concentrations of exoge-
nous estrone (180 and 540 pmol/l) were prepared from pooled
human male sera (Sigma–Aldrich). The control sera were divided
into 1 ml fractions and stored at 20 C. In addition, subcutaneous
adipose tissue from the breasts of 24 women (13 reduction plasty
and 11 cancer patients) was homogenized as described below,
pooled and used as control.
The flow chart of the method is shown in Fig.1. Weighed adipose
tissue (200 mg) was homogenized in 1 ml of distilled water. Tissue
and control serum samples (1 ml) were pipetted into disposable
borosilicate extraction tubes. [3H]Estrone (49,000 dpm in 10 ml of
ethanol) was added to adipose tissue samples obtained from the
control pool and used as an internal standard to measure recovery.
The samples were extracted four times with 3.5 volumes of diethyl
ether–ethyl acetate (1:1 by volume). The combined organic phases
were evaporated to dryness and weighed. A mean of 78% of the
original tissue sample’s (n = 56) weight was recovered in the organic
phase extract, calculated as [the weight of fat extracted from
adipose tissue (mg)/the weightof the original adipose tissue sample
(mg)]  100%. After extraction, the samples were subjected to
hydrophobic chromatography on Sephadex LH-20 in hexane–
chloroform (2:1 by volume) (chromatography I). The samples were
applied tothe columns in two0.3-ml aliquots of hexane–chloroform
(2:1 by volume). The interfering fatty substances were eluted in the
first lipoidal fraction with 10 ml of the same solvent and discarded.
The estrone fraction was eluted with 5 ml of methanol and
evaporated to dryness. To further purify the samples, a second
Sephadex LH-20 column chromatography (chromatography II) was
carried out in 9% methanol in toluene as described in [17]. The
sample was applied to the column in two 0.1 ml aliquots of 9%
methanol in toluene and estrone was eluted from the column in the
first fraction in 2.4 ml of the same solvent. The estrone fraction was
evaporated and dissolved in 1 ml of methanol. An aliquot of 50 mlwas taken from the control samples for liquid scintillation counting
to determine the recovery of the [3H]estrone internal standard
(Rack-beta, Wallac Oy, Turku, Finland). An aliquot of 250 ml was
taken for analysis by LC–MS/MS as described below.
2.4. LC–MS/MS method for determining estrone concentration in
adipose tissue
After evaporation to dryness, 30 ml of 13C3-estrone (internal
standard (IS), 2.5 nM) was added followed by 250 ml of water and
500 ml of 50 mM ammonium acetate/NH3 (pH 9). The samples
were extracted with 2 ml of diethyl ether. After mixing for 3 min,
the organic layer was collected and evaporated to dryness under
nitrogen. The residue was dissolved in 125 ml of 50% methanol.
Calibrators containing 25–1000 pmol/l of estrone were prepared in
50% methanol. 25 ml was injected on an LC–MS/MS system
equipped with an API 4000 triple quadrupole mass spectrometer
(AB Sciex, Concord, Canada). Peripherals included an Agilent series
1200 HPLC system with a binary pump (Waldbronn, Germany).
Separation was performed on a SunFire C18 column (2.1 100 mm;
Waters, Milford, MA). The mobile phase was a linear gradient
consisting of methanol (B) and water (A), at a flow rate of 300 ml/
min. The gradient was: 0 min, 50% B; between 0 and 5 min linearly
increased to 100% B; 5–8.5 min 100% B; between 8.5–9 min linearly
decreased to 50% B; and 9–15 min 50% B. The column was directly
connected to the electrospray ionisation probe. Estrone was
detected with the following transitions: m/z 269.1 to m/z 145.0
(quantification) and m/z 269.1 to m/z 142.9 (confirmation) and IS,
m/z 272.1 to m/z 148.0. Data were acquired and processed with the
Analyst Software (version 1.4.2; Sciex). All results were generated
in negative-ion mode: with the entrance potential at 8 V, the
declustering potential at 100 V, and the collision cell exit
Fig. 2. LC–MS/MS chromatograms of the lowest estrone calibrator and an adipose tissue sample showing no interference. LC–MS/MS chromatograms of (A) the 25 pmol/l
estrone calibrator and (B) a subcutaneous adipose tissue sample from the breast of a postmenopausal breast cancer patient containing 68 pmol/l estrone (480 pmol/kg as
calculated per tissue weight of 202 mg and corrected by the recovery of [3H]estrone of 71%). Upper panel: ion chromatogram following the fragmentation 269.1/145.0. Middle
panel: ion chromatogram following the fragmentation 269.1/142.9. Lower panel: ion chromatogram following the fragmentation of 272.1/148.0 of IS (13C3-estrone internal
standard). Y-axis: Intensity, cps.
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Table 1
Clinical characteristics as well as estrone concentrations in subcutaneous adipose
tissue from the breast and in serum in postmenopausal women with breast cancer
and reduction mammoplasty control women.
Breast cancer Control P-value
n = 13 n = 11
Age, years 63 (54–70) 60 (54–75) 0.228
Years from menopause 11 (3–28) 11 (0.5–23) 0.628
Body mass index, kg/m2 25 (20–34) 29 (22–38) 0.150
Waist to hip ratio 0.87 (0.76–1.0) 0.93 (0.82–0.99) 0.035
Adipose tissue E1, pmol/kg
the mean of N1 and N2 922 (238-1 911) 893 (333-3 130) 0.494
N1 1 009 (245-1 672) 1 005 (353-2 426) 0.691
N2 781 (231-2 150) 816 (312-4 152) 0.392
Serum E1, pmol/la 111 (39-141) 72 (19-285) 0.132
The data are expressed as median (range). Statistically significant P-values are
bolded (P < 0.05, Mann–Whitney U-test). E1, estrone; N1, adipose tissue proximal to
the tumor; N2, adipose tissue distal to the tumor (breast cancer patients).
a Serum estrone as previously reported in Ref. [16].
Fig. 3. A positive correlation between estrone concentrations in subcutaneous
adipose tissue from the breast measured proximal and distal to the tumor. The
concentration of estrone in subcutaneous adipose tissue correlated positively
between two samples obtained from different parts of the breast (r = 0.818,
P < 0.001, n = 24; Spearman’s correlation). In postmenopausal women with breast
cancer, the adipose tissue concentration of estrone was determined proximal to the
tumor (N1) and distal to the tumor (N2) as described in the methods. *, Women
with breast cancer; , control women.
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for m/z 145 and 70 V for m/z 142.9, as determined by manual
tuning. Front-end electrospray settings for the MS/MS ionization
source were as follows: curtain gas, 20; GS1, 20; GS2, 30; CAD, 8;
temperature 525 C; and ion source at 4500 V. The mass
calibration and resolution adjustments for the resolving quadru-
poles (at 0.7 atomic mass units at full width and half height) were




Fig. 2 A shows LC–MS/MS chromatograms for the lowest
estrone calibrator of 25 pmol/l and IS. A typical chromatogram of
estrone in subcutaneous adipose tissue from the breast of a breast
cancer patient is shown in Fig. 2 B with no interference from the
tissue matrix components.
The intra-assay imprecision was 7% (180 pmol/l, n = 11) for the
low and 8% (540 pmol/l, n = 11) for the high control serum sample
(section 2.3). The intra-assay variation of endogenous estrone in
adipose tissue (four parallel determinations of control adipose
tissue pool, section 2.3) ranged from 9.9% to 20% in four separate
assays (mean, 16%).
The interassay imprecision of the control adipose tissue pool
was 10% in four consequent assays (mean concentration of estrone
in pooled adipose tissue, 1962 pmol/kg). The interassay coefficient
of variation of LC–MS/MS was 3.5% at 115 pmol/l concentration of
the estrone calibrator (number of assays, n = 14).
For analytical recovery, pooled adipose tissue from 16 breast
cancer and reduction plasty patients was spiked with 300 pmol/l or
600 pmol/l estrone. The mean (SD) analytical recoveries from three
parallel samples were 124% (6) and 117% (2), respectively. The
results were calculated by subtracting the value of adipose tissue
without added estrogen and correcting according to the recovery
of the tritiated internal standard. The mean recovery of [3H]estrone
added to control adipose tissue was 74% (SD 8.9; range, 53–85%;
number of determinations n = 26 in six assays).
The limit of quantification of estrone by LC–MS/MS was
10 pmol/l (signal to noise-ratio S/N = 10). If calculated for the
200 mg starting weight of adipose tissue, the limit of quantification
of estrone was approximately 70 pmol/kg, corrected for the mean
recovery of 74% of the method.
3.2. Concentration of estrone in subcutaneous adipose tissue from the
breast
The LC/MS–MS method for quantitative determination of
estrone was applied to adipose tissue samples previously obtained
from breasts of postmenopausal women with or without breast
cancer [16]. The clinical characteristics of the study subjects as well
as the concentrations of estrone in subcutaneous adipose tissue
from the breast and serum are shown in Table 1. The concentration
of estrone in adipose tissue did not significantly differ between
cancer and control women. The median concentration of estrone
was slightly but not significantly higher in N1 compared to N2 in
breast cancer patients as well as in reduction plasty control
subjects (P = 0.463, N1 vs. N2 in breast cancer patients; Wilcoxon
signed rank test). Instead, the estrone concentrations measured in
N1 and N2 correlated positively with each other in both groups
(r = 0.857, P < 0.001, n = 13, breast cancer patients; and r = 0.764,
P = 0.006, n = 11, reduction plasty control subjects; Spearman’s
correlation) (Fig. 3).
In all subjects, adipose tissue estrone concentration correlated
positively with the body mass index (mean estrone concentrationin adipose tissue vs. BMI; r = 0.575, P = 0.003, n = 24; Spearman’s
correlation).
A significant positive correlation between adipose tissue
estrone concentration and serum estrone was observed in breast
cancer patients only (Fig. 4). In reduction plasty control subjects,
there was no significant correlation between adipose tissue and
circulating estrone concentrations (r = 0.176, P = 0.627, n = 10).
4. Discussion
We developed a reproducible novel method for the quantitative
determination of estrone in adipose tissue. To the best of our
knowledge, this is the first study to report estrone levels in
subcutaneous adipose tissue from the breast by LC–MS/MS. The
sensitivity of the analytical method was adequate to determine
estrone levels in postmenopausal women. Moreover, no interfering
matrix effects were recognized after a careful purification of the
adipose tissue samples from the excess of lipoidal substances.
We determined the concentration of estrone in subcutaneous
adipose tissue from the breast in 24 postmenopausal women.
Fig. 4. Adipose tissue and serum estrone concentrations were positively related in
women with breast cancer. The concentration of estrone in subcutaneous adipose
tissue from the breast correlated positively with serum estrone concentration in
postmenopausal women with breast cancer (r = 0.800, P = 0.003, n = 11; Spearman’s
correlation). Adipose tissue estrone concentration is expressed as the mean of two
determinations (proximal and distal to the tumor).
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times higher compared with the serum levels, in agreement with a
previous study in abdominal subcutaneous adipose tissue by LC–
MS/MS as studied in four postmenopausal women [18]. Another
study in abdominal subcutaneous adipose tissue reported a
slightly lower mean concentration of estrone by LC–MS/MS in
eight postmenopausal subjects including women with gynecolog-
ical cancer [19]. Altogether, these data support the concept that
subcutaneous adipose tissue is a significant source of estrone in
postmenopausal women. This has also been demonstrated in
obese men with a ten-fold subcutaneous adipose tissue/plasma
gradient for estrone as analyzed by gas chromatography–mass
spectrometry, GC–MS [20].
The estrone concentrations presented here are in agreement
with previous determinations by RIA in fatty tissues from the
breast [9,10,13]. We observed a positive correlation between
adipose tissue and serum estrone concentrations in breast cancer
patients, in line with previous studies [9,15], but not in control
women. As estrone levels in adipose tissue exceed those in serum,
we assume that they could, in theory, influence serum estrone
levels. However, it is not clear how increased production of estrone
in breast cancer patients [21–23] could have an effect on serum
levels, as the adipose tissue estrone concentration was not higher
in women with breast cancer compared to control women.
As mentioned above, the concentrations of estrone in subcuta-
neous adipose tissue from the breast were comparable in subjects
with breast cancer and control women. Moreover, we did not find
any significant differences in estrone concentrations in adipose
tissue located distally or proximally to the tumor, in line with two
previous studies [13,14]. Instead, we detected a strong positive
correlation between estrone concentrations analyzed from differ-
ent adipose tissue samples from the same subject that adds to the
reliability of the analytical method. Falk et al. used different
methodology and reported estrone levels by RIA in nine pre- and
postmenopausal women together in the oil harvested from breast
adipocytes [14]. In addition to adipocytes, adipose tissue contains
varying amounts of connective and other tissues. We studied
subcutaneous adipose tissue from the breast and found that
approximately 80% of the sample's weight was recovered in the
lipophilic fraction after extraction with organic solvents. Therefore
we also calculated the concentrations of estrone relative to the
amount of fat extracted from adipose tissue samples, however, thisdid not change the results to any significant extent (data not
shown).
In conclusion, we describe a reproducible and reliable LC–MS/
MS method to measure estrone in postmenopausal adipose tissue.
Subcutaneous adipose tissue from the breast contained relatively
high concentrations of estrone compared to serum levels in
postmenopausal women.
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